Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record.

Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis

Brink, Mikael, Hansson, Monika, Mathsson, Linda, Jakobsson, Per‐Johan, Holmdahl, Rikard, Hallmans, Göran, Stenlund, Hans, Rönnelid, Johan, Klareskog, Lars, Rantapää‐Dahlqvist, Solbritt·2013·Arthritis & Rheumatism

Abstract

Objective: The presence of antibodies against cyclic citrullinated peptides has been demonstrated to precede the onset of symptoms of rheumatoid arthritis (RA) by several years. The aim of this study was to analyze antibodies against 10 citrullinated autoantigen‐derived peptides for reactivity before the onset of RA symptoms. Methods: A case–control study was conducted within the Medical Biobank of Northern Sweden. The study was performed in 409 individuals, 386 of whom donated 717 blood samples before the onset of symptoms of RA (pre‐patients). The median period of time predating the onset of RA was 7.4 years. A total of 1,305 population‐based control subjects were also studied. Antibodies to 10 citrullinated peptides, fibrinogen α573 (Fibα573), Fibα591, Fibβ36–52, Fibβ72, Fibβ74, α‐enolase (citrullinated α‐enolase peptide 1 [CEP‐1]), triple‐helical type II collagen peptide C1 (citC1 III ), filaggrin, vimentin 2–17 (Vim2–17), and Vim60–75, were analyzed using a microarray system. Results: The fluorescence intensity of antibodies against Fibβ36–52, Fibβ74, CEP‐1, citC1 III , and filaggrin was significantly increased in pre‐patients compared with controls ( P < 0.001). The levels of the earliest‐detectable antibodies (Fibα591 and Vim60–75) fluctuated over time, with only a slight increase after the onset of disease. The frequency of antibodies against Fibβ36–52, CEP‐1, and filaggrin increased gradually, reaching the highest levels before symptom onset. The frequency of a cluster of antibodies, citC1 III , Fibα573, and Fibβ74, increased only slightly before the onset of symptoms but increased prominently after disease onset. The odds ratio for the development of RA in individuals expressing both CEP‐1 and Fibβ36–52 antibodies (using data from samples obtained <3.35 years predating symptom onset) was 40.4 (95% confidence interval 19.8–82.3) compared with having either antibody alone. Conclusion: Development of an immune response toward citrullinated peptides is initially restricted but expands with time to induce a more specific response, with levels, particularly those of antibodies against CEP‐1, Fibβ36–52, and filaggrin, increasing during the predating time period closer to the onset of symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.37835

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 194

Metadata

Authors
Brink, M., Hansson, M., Mathsson, L., Jakobsson, P., Holmdahl, R., Hallmans, G., Stenlund, H., Rönnelid, J., Klareskog, L., & Rantapää‐Dahlqvist, S.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2013-03-28
Volume
65
Issue
4
Pages
899-910
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W1913865297
Cited by
194
References
0
FWCI
20.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis. https://app.cochat.ai/papers/10.1002/art.37835
The paper
Brink, M., Hansson, M., Mathsson, L., Jakobsson, P., Holmdahl, R., Hallmans, G., Stenlund, H., Rönnelid, J., Klareskog, L., & Rantapää‐Dahlqvist, S. (2013). Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.37835

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.